A case of prolonged remission after discontinuation of biological therapy in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps

Budkovaya M.A.; Ryazantsev S.V.; Rebrova S.A.

doi:https://doi.org/10.17116/otorino20248906199

Budkovaya M.A.

St. Petersburg Research Institute of Ear, Throat, Nose and Speech;
St. Petersburg State University

ORCID: 0000-0003-0219-1413

Ryazantsev S.V.

St. Petersburg Research Institute of Ear, Throat, Nose and Speech

ORCID: 0000-0001-5306-8875

Rebrova S.A.

St. Petersburg Research Institute of Ear, Throat, Nose and Speech

ORCID: 0000-0003-0451-8635

A case of prolonged remission after discontinuation of biological therapy in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps

Authors:

Budkovaya M.A., Ryazantsev S.V., Rebrova S.A.

More about the authors

Journal: Russian Bulletin of Otorhinolaryngology. 2024;89(6): 99‑106

DOI: 10.17116/otorino20248906199

Read: 1304 times

Contact the author

Table of contents

To cite this article:

Budkovaya MA, Ryazantsev SV, Rebrova SA. A case of prolonged remission after discontinuation of biological therapy in a patient with severe uncontrolled chronic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;89(6):99‑106. (In Russ.)
https://doi.org/10.17116/otorino20248906199

Подписка 2026 Вестник оториноларингологии (Russian Bulletin of Otorhinolaryngology)

Использование инфографики авторами научных работ

Recommended articles:

Antifungal immunity in patients with chronic rhinosinusitis with nasal polyps. Russian Bulletin of Otorhinolaryngology. 2024;(6):40-45

Monoclonal antibodies in the treatment of recurrent polyposis rhinosinusitis. Literature review. Russian Bulletin of Otorhinolaryngology. 2025;(4):96-104

Efficacy of dupilumab application in bullous pemphigoid proceeding in presence of bronchial asthma. Russian Journal of Clinical Dermatology and Venereology. 2025;(2):204-209

Synergistic efficiency of preformed physical factors and dupilumab in the treatment of polypous rhinosinusitis. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(2):16-23

Relationship between oxidative stress patterns and proinflammatory cytokines in patients with polypous rhinosinusitis under the course of therapeutic physical factors. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(2):42-49

Laboratory considerations in assessing efficacy and safety of biologic therapy in the elderly (as Exemplified by Asthma). Laboratory Service. 2025;(2):29-32

Mechanisms of additivity of physiotherapeutic factors in complex therapy of polypous rhinosinusitis complicated by comorbidities. Regenerative Biotechnologies, Preventive, Digital and Predictive Medicine. 2025;(3):5-11

Sinonasal pathology in patients with primary ciliary dyskinesia. Russian Rhinology. 2025;(3):223-232

Abstract:

Currently, targeted biological therapy is an innovative and highly effective approach in the treatment of severe chronic rhinosinusitis with nasal polyps (CRSwNP) associated with T2 inflammation that is uncontrolled by standard treatment methods. The article presents the first experience of long-term observation of a patient who, one year after the start of targeted biological therapy with dupilumab, independently stopped the treatment due to complete relief of symptoms of CRSwNP, despite recommendations to continue therapy to maintain control. At the same time, one year after the refusal of biological therapy, the patient showed persistent clinical remission in relation to the symptoms of CRSwNP, confirmed by the results of videoendoscopic examination of the nasal cavity and computed tomography of the sinuses. The described clinical observation emphasizes the need to develop a personalized approach to prescribing immunobiological therapy in patients with CRSwNP and a more detailed study of the criteria for a super-response to this treatment.

Keywords:

rhinosinusitis with nasal polyp

dupilumab

long-term remission

targeted biological therapy

cancel

Authors:

Budkovaya M.A.

St. Petersburg Research Institute of Ear, Throat, Nose and Speech;
St. Petersburg State University

ORCID: 0000-0003-0219-1413

Ryazantsev S.V.

St. Petersburg Research Institute of Ear, Throat, Nose and Speech

ORCID: 0000-0001-5306-8875

Rebrova S.A.

St. Petersburg Research Institute of Ear, Throat, Nose and Speech

ORCID: 0000-0003-0451-8635

Received:

28.10.2024

Accepted:

12.11.2024

Close metadata

References:

Lazareva AM, Kolenchukova OA, Smirnova SV. Theories of the pathogenesis of polypous rhinosinusitis and the asthmatic triad. Russian Bulletin of Otorhinolaryngology. 2023;88(6):73-80. (In Russ.). https://doi.org/10.17116/otorino20238806173
Kuzubova NA, Titova ON. T2-associated diseases: focus on the comorbid patient. Meditsinskij sovet. 2020;(17):57-64. (In Russ.). https://doi.org/10.21518/2079-701X-2020-17-57-64
Budkovaya MA, Ryazantsev SV, Dvoryanchikov VV, Rebrova SA, Maltseva GS. Prospects for the Use of Biological Therapy in Chronic Rhinosinusitis with Nasal Polyps and Other T2-Associated Immuno-Mediated Inflammatory Diseases. E`ffektivnaya farmakoterapiya. 2021;17(18):16-20. (In Russ.). https://doi.org/10.33978/2307-3586-2021-17-18-16-20
Fokkens WJ, Lund VJ, Hopkins C, Hellings PW, Kern R, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Alobid I, Terezinha Anselmo-Lima W, Bachert C, Baroody F, von Buchwald C, Cervin A, Cohen N, Constantinidis J, De Gabory L, Desrosiers M, Diamant Z, Douglas RG, Gevaert PH, Hafner A, Harvey RJ, Joos GF, Kalogjera L, Knill A, Kocks JH, Landis BN, Limpens J, Lebeer S, Lourenco O, Meco C, Matricardi PM, O’Mahony L, Philpott CM, Ryan D, Schlosser R, Senior B, Smith TL, Teeling T, Tomazic PV, Wang DY, Wang D, Zhang L, Agius AM, Ahlstrom-Emanuelsson C, Alabri R, Albu S, Alhabash S, Aleksic A, Aloulah M, Al-Qudah M, Alsaleh S, Baban MA, Baudoin T, Balvers T, Battaglia P, Bedoya JD, Beule A, Bofares KM, Braverman I, Brozek-Madry E, Richard B, Callejas C, Carrie S, Caulley L, Chussi D, de Corso E, Coste A, El Hadi U, Elfarouk A, Eloy PH, Farrokhi S, Felisati G, Ferrari MD, Fishchuk R, Grayson W, Goncalves PM, Grdinic B, Grgic V, Hamizan AW, Heinichen JV, Husain S, Ping TI, Ivaska J, Jakimovska F, Jovancevic L, Kakande E, Kamel R, Karpischenko S, Kariyawasam HH, Kawauchi H, Kjeldsen A, Klimek L, Krzeski A, Kopacheva Barsova G, Kim SW, Lal D, Letort JJ, Lopatin A, Mahdjoubi A, Mesbahi A, Netkovski J, Nyenbue Tshipukane D, Obando-Valverde A, Okano M, Onerci M, Ong YK, Orlandi R, Otori N, Ouennoughy K, Ozkan M, Peric A, Plzak J, Prokopakis E, Prepageran N, Psaltis A, Pugin B, Raftopulos M, Rombaux P, Riechelmann H, Sahtout S, Sarafoleanu CC, Searyoh K, Rhee CS, Shi J, Shkoukani M, Shukuryan AK, Sicak M, Smyth D, Sindvongs K, Soklic Kosak T, Stjarne P, Sutikno B, Steinsvag S, Tantilipikorn P, Thanaviratananich S, Tran T, Urbancic J, Valiulius A, Vasquez de Aparicio C, Vicheva D, Virkkula PM, Vicente G, Voegels R, Wagenmann MM, Wardani RS, Welge-Lussen A, Witterick I, Wright E, Zabolotniy D, Zsolt B, Zwetsloot CP. European Position Paper on Rhinosinusitis and Nasal Polyps. Rhinology. 2020;58(Suppl S29):1-464. https://doi.org/10.4193/Rhin20.600
Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD, Mannent LP. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638-1650. https://doi.org/10.1016/S0140-6736(19)31881-1
Han JK, Bachert C, Fokkens W, Desrosiers M, Wagenmann M, Lee SE, Smith SG, Martin N, Mayer B, Yancey SW, Sousa AR, Chan R, Hopkins C; SYNAPSE study investigators. Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine. 2021;9(10):1141-1153. https://doi.org/10.1016/S2213-2600(21)00097-7
Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M, Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C. Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. Journal of Allergy and Clinical Immunology. 2020;146(3):595-605. https://doi.org/10.1016/j.jaci.2020.05.032
Fokkens WJ, Viskens AS, Backer V, Conti D, De Corso E, Gevaert P, Scadding GK, Wagemann M, Bernal-Sprekelsen M, Chaker A, Heffler E, Han JK, Van Staeyen E, Hopkins C, Mullol J, Peters A, Reitsma S, Senior BA, Hellings PW. EPOS/EUFOREA update on indication and evaluation of Biologics in Chronic Rhinosinusitis with Nasal Polyps 2023. Rhinology. 2023;61(3):194-202. https://doi.org/10.4193/Rhin22.489
De Corso E, Pasquini E, Trimarchi M, La Mantia I, Pagella F, Ottaviano G, Garzaro M, Pipolo C, Torretta S, Seccia V, Cantone E, Ciofalo A, Lucidi D, Fadda GL, Pafundi PC, Settimi S, Montuori C, Anastasi F, Pagliuca G, Ghidini A, Cavaliere C, Maffei M, Bussu F, Gallo S, Canevari FRM, Paludetti G, Galli J; Dupireal Italian Study Group. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP): a multicentric observational phase IV real-life study (DUPIREAL). Allergy. 2023;78(10):2669-2683. https://doi.org/10.1111/all.15772
Galletti C, Ragusa M, Sireci F, Ciodaro F, Barbieri MA, Giunta G, Grigaliute E, Immordino A, Lorusso F, Dispenza F, Freni F, Galletti F, Gallina S, La Mantia I, Galletti B. Dupilumab in chronic rhinosinusitis with nasal polyps: Real life data in a multicentric Sicilian experience. Otolaryngology. 2024;45(1):104106. https://doi.org/10.1016/j.amjoto.2023.104106
Larin RA, Mokeeva PP, Grishin AS. Experience of biological therapy in severe forms of chronic rhinosinusitis with nasal polyps in the conditions of regional healthcare. Russian Bulletin of Otorhinolaryngology. 2022;88(2):51-58. (In Russ.). https://doi.org/10.17116/otorino20228802151
Eisenbach N, Matot S, Nemet A, Sela E, Marshak T, Ronen O. Sino-nasal outcome test-22: Cross-cultural adaptation and validation In Russian speaking patients. Clinical Otolaryngology. 2020;45(3): 350-356. https://doi.org/10.1111/coa.13505
Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, Canonica GW, Deneyer L, Desrosiers M, Diamant Z, Han J, Heffler E, Hopkins C, Jankowski R, Joos G, Knill A, Lee J, Lee SE, Mariën G, Pugin B, Senior B, Seys SF, Hellings PW. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy. 2019;74:2312-2319. https://doi.org/10.1111/all.13875
Fokkens WJ, De Corso E, Backer V, Bernal-Sprekelsen M, Bjermer L, von Buchwald C, Chaker A, Diamant Z, Gevaert P, Han J, Hopkins C, Hox V, Klimek L, Lund VJ, Lee S, Luong A, Mullol J, Peters A, Pfaar O, Reitsma S, Toppila-Salmi S, Scadding GK, Sedaghat AR, Viskens AS, Wagenmann M, Hellings PW. EPOS2020/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology. 2024;62(3):287-298. https://doi.org/10.4193/Rhin23.415
Bachert C, Han JK, Wagenmann M, Hosemann W, Lee SE, Backer V, Mullol J, Gevaert P, Klimek L, Prokopakis E, Knill A, Cavaliere C, Hopkins C, Hellings P. EUFOREA expert board meeting on uncontrolled severe chronic rhinosinusitis with nasal polyps (CRSwNP) and biologics: Definitions and management. Allergy and Clinical Immunology. 2021;147(1):29-36. https://doi.org/10.1016/j.jaci.2020.11.013